Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.56 |
| ▸ | NPY1R | P25929 | 13/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL960822 | 0.78 | KCNH2 (0.77) | KCNH2NPY1RBRD4 | |
| SCHEMBL960171 | 0.78 | KCNH2 (0.46) | KCNH2NPY1R | |
| SCHEMBL962739 | 0.77 | KCNH2 (0.45) | KCNH2NPY1R | |
| SCHEMBL963131 | 0.74 | KCNH2 (0.42) | KCNH2NPY1RBRD4 | |
| SCHEMBL962751 | 0.74 | KCNH2 (0.42) | KCNH2NPY1R | |
| SCHEMBL963713 | 0.73 | KCNH2 (0.41) | KCNH2NPY1R | |
| SCHEMBL964441 | 0.72 | NPY1R (0.81) | KCNH2NPY1R | |
| SCHEMBL13688195 | 0.72 | NPY1R (0.73) | KCNH2NPY1R | |
| SCHEMBL3413170 | 0.68 | NPY1R (0.67) | KCNH2NPY1R | |
| SCHEMBL7017602 | 0.68 | NPY1R (0.53) | KCNH2NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2264026-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264026-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009110510-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | 萬有製薬株式会社 (JP) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | NPY4R, NPY1R, NPY2R | KCNH2 1295/4885NPY1R 2/4885BRD4 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.